We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

119 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

688% more call options, than puts

Call options by funds: $12.8M | Put options by funds: $1.63M

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

6% more funds holding

Funds holding: 112 → 119 (+7)

0% more capital invested

Capital invested by funds: $215M → $215M (+$374K)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

4.77% less ownership

Funds ownership: 51.24% → 46.47% (-4.8%)

14% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 36

Holders
119
Holders Change
+7
Holders Change %
+6.25%
% of All Funds
1.71%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
20
Increased
31
Reduced
36
Closed
13
Calls
$12.8M
Puts
$1.63M
Net Calls
+$11.2M
Net Calls Change
+$10.5M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.77M
2
BCP
BlackBarn Capital Partners
New York
+$5.36M
3
FCM
FourWorld Capital Management
New York
+$4.95M
4
CCP
Corbin Capital Partners
New York
+$2.21M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.17M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$13.3M
2
ACM
ADAR1 Capital Management
Texas
-$3.61M
3
Millennium Management
Millennium Management
New York
-$3.36M
4
TSC
Two Seas Capital
New York
-$3.11M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
101
Russell Investments Group
United Kingdom
$8.12K +$2.29K +883 +39%
S
102
SignatureFD
Georgia
$7.79K – – –
National Bank of Canada
103
National Bank of Canada
Quebec, Canada
$4.92K -$285 -110 -6%
TRCT
104
Tower Research Capital (TRC)
New York
$4.8K -$11.4K -4,396 -70%
Carson Wealth (CWM LLC)
105
Carson Wealth (CWM LLC)
Nebraska
$4K +$4.03K +1,554 +1,087%
US Bancorp
106
US Bancorp
Minnesota
$3.74K +$3.76K +1,451 New
BFEC
107
Benjamin F. Edwards & Company
Missouri
$3K – – –
QCG
108
Quadrant Capital Group
Ohio
$2.27K +$1.56K +601 +217%
CPG
109
Cornerstone Planning Group
New Jersey
$2.12K +$2.02K +782 New
HIA
110
Harbor Investment Advisory
Maryland
$2.07K – – –
FDCDDQ
111
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.06K – – –
PA
112
Parallel Advisors
California
$1.42K – – –
Daiwa Securities Group
113
Daiwa Securities Group
Japan
$1K – – –
HFS
114
Hantz Financial Services
Michigan
$1K – – –
LC
115
Lindbrook Capital
California
$733 – – –
PWMG
116
Private Wealth Management Group
New Jersey
$625 – – –
PNC Financial Services Group
117
PNC Financial Services Group
Pennsylvania
$537 – – –
GI
118
GAMMA Investing
California
$482 – – –
AWM
119
Avior Wealth Management
Nebraska
$61 +$62 +24 New
Assenagon Asset Management
120
Assenagon Asset Management
Luxembourg
– -$2.04M -817,574 Closed
TC
121
Tejara Capital
United Kingdom
– -$450K -180,077 Closed
Point72 Asset Management
122
Point72 Asset Management
Connecticut
– -$263K -105,000 Closed
CM
123
Caption Management
Oklahoma
– -$111K -42,736 Closed
State Board of Administration of Florida Retirement System
124
State Board of Administration of Florida Retirement System
Florida
– -$89.5K -35,820 Closed
VF
125
Virtu Financial
New York
– -$45K -17,923 Closed
2 3 4
5
6

ABUS Hedge Fund Activity: Q1 2024 in Review

119 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2024, worth a combined $215M — up 0.17% from $215M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ABUS positions and 13 closed out — a net gain of 7 holders — while 31 added to existing stakes and 36 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $7.77M. The largest seller was Morgan Stanley, cutting an estimated $13.3M.

  • 119 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2024, up from 112 in Q4 2023.
  • Funds reported $215M of Arbutus Biopharma stock for Q1 2024, up 0.17% quarter-over-quarter.
  • 20 funds opened new Arbutus Biopharma positions in Q1 2024 and 13 closed out, a net change of +7 holders.
  • The largest Arbutus Biopharma buyer in Q1 2024 was Adage Capital Partners, an estimated $7.77M added.
  • The largest Arbutus Biopharma seller in Q1 2024 was Morgan Stanley, an estimated $13.3M sold.

Based on aggregated 13F filings for Q1 2024.